Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 13, 2017
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases, today
View HTML
Toggle Summary AGTC and the Foundation Fighting Blindness Announce Partnership Agreement
AGTC Grant Will Support FFB's Patient Registry and Local Programs
View HTML
Toggle Summary AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16, 2017
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16, 2017 GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ( AGTC ), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based
View HTML
Toggle Summary Research Published in Molecular Therapy Identifies Optimal Gene-based Therapeutic Construct for X-Linked Retinitis Pigmentosa
Preclinical research led by scientists from the University of Pennsylvania demonstrates effective delivery and expression of functional gene sequences, positive effects on retinal structure and function, and improved visual navigation in animal models
View HTML
Toggle Summary AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Appoints William Sullivan as Chief Financial Officer, Andrew Ashe Named General Counsel
Seasoned executives bring extensive operating and financial experience
View HTML
Toggle Summary IND-Enabling Study Data Published in Human Gene Therapy Clinical Development Support Clinical Development of AGTC-402 for the Treatment of CNGA3-deficient Achromatopsia
Preclinical study demonstrates that AGTC-402 significantly improved vision in a large animal model of achromatopsia
View HTML
Toggle Summary AGTC Announces Topline Safety Data for X-Linked Retinoschisis Phase 1/2 Study
GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced topline
View HTML
Toggle Summary Data Published in Molecular Therapy Demonstrate Five-Year Response Following a Single Dose of an Investigational Gene-Based Therapy for Alpha-1 Antitrypsin (AAT) Deficiency
Clinical study led by researchers at the University of Massachusetts Medical School demonstrates sustained protein expression and improvements in multiple indicators of AAT biological activity
View HTML
Visionary science for life changing cures.